Raymond James Financial
STIM icon

Raymond James Financial’s Neuronetics STIM Stock Holding History

Raymond James Financial’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,164
Closed -$66K – 5328
2025
Q3 		$66K Buy
24,164
+13,587
+128% +$48.3K ﹤0.01% 4796
2025
Q2 		$36.9K Buy
+10,577
New +$41.8K ﹤0.01% 5302

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's STIM Position: Q4 2025 in Review

Raymond James Financial sold out of Neuronetics (STIM) in Q4 2025, closing a stake of 24,164 shares — an estimated $66K sold.

Raymond James Financial first reported a position in STIM in Q2 2025 and held it in 2 quarters. The position peaked at $66K in Q3 2025. 95 funds tracked by Wall St. Rank hold STIM as of Q4 2025.

  • Raymond James Financial reported no remaining Neuronetics position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 24,164 Neuronetics shares in Q4 2025, an estimated $66K.
  • Raymond James Financial first reported a position in Neuronetics in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Neuronetics position peaked at $66K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Neuronetics as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.